Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

2.48USD
22 May 2017
Change (% chg)

$0.13 (+5.53%)
Prev Close
$2.35
Open
$2.48
Day's High
$2.50
Day's Low
$2.44
Volume
124,166
Avg. Vol
62,016
52-wk High
$2.53
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Verastem director Barberich buys 30,000 shares of co's common stock on May 15
Wednesday, 17 May 2017 08:28am EDT 

May 17 (Reuters) - Verastem Inc :Verastem Inc director Timothy Barberich reports purchase of 30,000 shares of co's common stock on May 15 at average price of $2.45 per share - SEC filing.  Full Article

Verastem Q1 loss per share $0.35
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Verastem Inc ::Verastem reports first quarter 2017 financial results.Q1 loss per share $0.35.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.  Full Article

Verastem reports year-end 2016 financial results
Thursday, 23 Mar 2017 04:01pm EDT 

Verastem Inc - : Verastem reports year-end 2016 financial results . Expect to have sufficient cash, cash equivalents and investments to fund our research and development programs and operations into 2018 . Net loss for year ended December 31, 2016 $0.99 per share .As of December 31, 2016, Verastem had cash, cash equivalents and investments of $80.9 million compared to $110.3 million as of December 31, 2015.  Full Article

Infinity expects net loss for 2017 in the range of $40 mln to $50 mln
Monday, 9 Jan 2017 08:03am EST 

Infinity Pharmaceuticals Inc : Infinity provides 2017 goals and financial guidance . Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million . Infinity Pharmaceuticals Inc - expects net loss for 2017 to range from $40 million to $50 million. . Infinity Pharmaceuticals - updated cash runway expectation assumes receiving $6.0 million milestone payment from verastem for positive duo study results .Infinity Pharmaceuticals sees existing cash, cash equivalents, available-for-sale securities at Dec 31 2016 to be adequate to satisfy capital needs into Q1 2019.  Full Article

Verastem reports Q2 loss per share $0.23
Monday, 8 Aug 2016 08:40am EDT 

Verastem Inc : Verastem reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S .Expect to have sufficient cash, cash equivalents and short-term investments to fund research and development programs and operations into 2018.  Full Article

Verastem Q1 loss per share $0.22
Monday, 9 May 2016 04:05pm EDT 

Verastem Inc : Expect to have sufficient cash, cash equivalents,short-term investments to fund research and development programs and operations into 2018 . Verastem reports first quarter 2016 financial results . Q1 loss per share $0.22 .Q1 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

Verastem Announces Reduction of Workforce
Thursday, 8 Oct 2015 04:46pm EDT 

Verastem Inc:Says reduction of its workforce by approximately 50% to 20 full time employees.All affected employees will receive severance pay and outplacement assistance.As a result of the reduction in force and associated costs, Verastem estimates annual savings of about $4.9 million in cash operating expenses on a going forward basis, with estimated one-time severance and related costs of about $825,000 over Q4 2015 and the Q1 2016.  Full Article

More From Around the Web

BRIEF-Verastem director Barberich buys 30,000 shares of co's common stock on May 15

* Verastem Inc director Timothy Barberich reports purchase of 30,000 shares of co's common stock on May 15 at average price of $2.45 per share - SEC filing Source text: (http://bit.ly/2pKDBMW) Further company coverage: